Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
JotieP Your understanding of the conversion being at the discretion of the subscriber is the same as my understanding. However, I believe the the term was chosen such that the share price will look much more attractive in early 2024. If you are so negative on BCARTs prospects over the next few years why do you invest in BCART? While I do fault BCART for the slow pace in pursuing registrations and the sometimes flubbed PR statements I do believe the premise that they are selling a differentiated product into a worldwide MDx market that is growing at 20% annually. The time and expense to gain marketing approvals and build out the distribution network have been considerable. However, I have to believe that at some point well before 2024 these investments become a tailwind. I often refer to my investment in GHDX as an example. The share price did nothing for two years while they continued to rack up positive publications but then tripled in a few weeks after the results of the Tailorx trial on OncotypeDX Breast were published in the NEJM and were presented at ASCO. GHDX was profitable from that point on. BCART could well be in the same type of situation. In the meantime BCART has to do the obvious, build out the menu offerings and gain full diagnostic and insurance reimbursement approvals. As I pointed out some time ago, the cost of Idylla assays were running at half the US reimbursement rates for KRAS, NRAS, MSI. Diagnostic use approval would unlock a large lucrative market. I anticipate that they will price both consoles and cartridges at attractive rates for the early adopters. Unfortunately, NGS costs are coming down and they are getting better at speeding up the result TAT, Therefore, the differentiation advantage is dissipating (hence my always harping on this subject). BCART is promising the long awaited sales growth inflection point in 2021. Given the lingering Covid disruption I'd not be surprised if this inflection point slides into 2022. But I believe the share price will reflect improved prospects well before 2024. FL
@FL there is a difference between being negative about BCART in a way that i would no longer invest in it, and expecting the share price will be trippled in 3 years. It's a combination of both. I do believe in Biocartis on the long term, but i don't believe in the share price being attractive enough for the subscribers of the convertible to convert the loan. The due date of the convertible will be there fast enough. BCART is my highest risk/reward stock. My pessimism and hope counter eachother. Also take into account that lack of knowledge is a trigger for fear/pessimism. Most of my stocks are value-stocks and are easily calculatable. i know the PE, ROCE, etc etc of all my stocks. BCART is more difficult to know where the company is heading. it's more like a jump in the dark... You do a great job in providing a lot of information here, which I appreciate a lot. It might however be very clear to you, due to your knowledge on BCART and it's market, what should happen etc ... but for me, with less knowledge ... i get stuck with 'we'll get the SARS-COV2 test approved in the coming weeks' from a long time ago, the returned idylla in Q4 2020 report which was apparently installed but not sold, ... . The metrics that i can calculate are showing me the growth rate is too slow now. So conclusion, the combination of lack of knowledge and the highest risk/reward makes me pessimistic / cautious. I'm however not afraid to sell my stocks with losses. If i would think that it would be the way forward, i would push the button. So far i didn't do it. PS: i'm not that concerned about the share price itself. It's more about the growth rate, the lobby skills of BCART, and (potential) competitors. A low share price can even be good... If BCART could refinance itself based on impressive growth rates, and the convertibles are not converted due to a low share price ... that would be great. No dillusion of shares and new liquidity due to good growth rates... but that's dreaming for now. Looking forward to the forecast 2021! kind regards and nice weekend, JotieP
JotieP I estimate that the size of the RUO market in the U.S. is only about 5% of the overall diagnostic market. I keep looking for a reference confirming the sized difference but have not found something to back up my estimate. I find it hard to understand how the present growth metrics get extrapolated out 3 years without consideration of the unlocking of what could be 95% of the market. Much of what happens in the US is based on insurance reimbursement rates. The ability to provide an assay at half the cost of a competitor and half the reimbursement rate has the potential to unlock tremendous growth. I believe this is much more pronounced in the US than the EU since the reimbursement rates are much higher, BCART does not break out the numbers geographically to allow us to assess the difference in adoption rates. 2021 is most likely going to be a very lumpy sales year as the shift from COVID assays to Oncology begins to occur. BCART is one of my larger speculations but the position sizing is about 3% of my overall portfolio. I spend more time on it than other investments since I like the MDx field. We must start to see success in registering and commercializing Idylla outside the US. Have a good weekend. FL
I was in a hurry. The last sentence should read EU. FL
Thanks,FL JotieP,voor jullie bijdragen en vooruitzichten over hoe we van uit de huidige "stilstand" een groeipad hopen te bereiken.De aandeelhouders van het eerste uur hopen samen met jullie ook op een positieve uitkomst.Ok,erg positief kom ik momenteel niet over, maar dit heeft het management zich over zichzelf uitgeroepen,volgens mij en dit dan door telkens de kleine aandeelhouders voor voldongen feiten te plaatsen bij de zoveelste KO.De volgende vooruitzichten zullen volgens mij bepalend zijn of we als aandeelhouders blijven zitten of we er de stekker eruit trekken.Is dit hard? Ja!Maar sedert 2015 is het moeilijk om een "serieuze"belegging te vinden die ze nog meer heeft ontgoocheld dan Blocartis.Rudi Marien had het bij het rechte eind, jaren terug al! Je mag je niet voorstellen hoeveel andere beleggingen in die periode
De recentste bedrijfspresentatie van januari eens doorgenomen, zeer interessante lectuur voor iedere aandeelhouder. Geeft een gedetailleerd beeld waar ze willen in investeren in de komende jaren.
RUF RTR schreef op 8 februari 2021 13:15 :
De recentste bedrijfspresentatie van januari eens doorgenomen, zeer interessante lectuur voor iedere aandeelhouder.
Geeft een gedetailleerd beeld waar ze willen in investeren in de komende jaren.
Dag RUF RTR, inderdaad een zeer duidelijke presentatie, vraagje van mijn kant: delen van deze presentatie werden ook tijdens de laatste conf call besproken. Op slide / pagina 27 staat een overzicht van de potentiële adressable market in oncologie. Weet jij nog welke tijdshorizon ze plakken op short term, mid-term en long term ? Vb, short term is dat 1-2 jaar, mid term 5 jaar en long term 10 jaar ? thanks
tomtesteron schreef op 10 februari 2021 09:07 :
[...]
Dag RUF RTR,
inderdaad een zeer duidelijke presentatie,
vraagje van mijn kant: delen van deze presentatie werden ook tijdens de laatste conf call besproken.
Op slide / pagina 27 staat een overzicht van de potentiële adressable market in oncologie. Weet jij nog welke tijdshorizon ze plakken op short term, mid-term en long term ? Vb, short term is dat 1-2 jaar, mid term 5 jaar en long term 10 jaar ?
thanks
Dag tomtesteron, Is een belangrijke opmerking. Tijdshorizon in biotech en farma is natuurlijk zeer relatief. Op 5 jaar kan jouw technologie voorbijgestreefd zijn, daarenboven hangt ook zeer veel af van goedkeuring door EMA en FDA. Denk dat jouw inschatting van short term, mid term en long term vrij realistisch is. Iedereen hoopt natuurlijk altijd op een snellere goedkeuring, ontwikkeling en marktintroductie maar het blijft een moeilijke evenwichtsoefening. Kijk bvb ook nu maar naar de vaccins tegen Covid-19, deze werden ontwikkeld in een recordtempo maar er is weinig onderzoek gedaan naar mogelijke bijwerkingen. Deze presentatie geeft me vertrouwen naar de nabije toekomst toe.
Beste forum, ik verdiep me momenteel in Biocartis. Hierbij merk ik dat het aantal geïnstalleerde Idylla systemen jaar na jaar stijgt, de groei is redelijk lineair over de laatste jaren. Dit terwijl men zou kunnen verwachten dat dit toch "exponentieel" zou zijn (misschien te weinig kennis nog over dit soort platformen). Is hiervoor een verklaring en komt die extra groei nog jullie inziens? Tweede vraag, hoeveel is de geïnstalleerde productiecapaciteit van cartridges voor Idylla platform? Alvast bedankt voor de input!
Thole, My belief is that two factors weigh on the current rate of uptake: 1) Idylla is registered in the EU for diagnostic use for only a handful of assays. Outside of the EU (in the US, China, Japan, etc.) Idylla assays can only be used for research purposes (a much smaller market). They have completed the testing program for validation and will be filing for diagnostic use registration for several critical assays later the year. Listen on the 25th for more information on the exact schedule. 2) The number of assays has been limited. For example, with the release of the gene fusion assay in the next few weeks they will finally be reaching the point where the majority of actionable lung cancer targets (i.e, cancers with genetic targets for which approved drugs exist) will finally exist. Listen for updates on the CDx partnerships. Filing for approval of Idylla registration for use as a CDx for say AZN's Tagrisso or BMS Optivo will be critical in BCART being able to marshal the large Pharma sales forces to help sell Idylla products. These developments should be apparent in the EU 1st and then expand to the US, China etc. as the IVD registrations are approved. Finally, the 2nd manufacturing line that is up and running allows for production of just over a million cartridges a year. The 3rd line is likely to be located in China. Management is saying that this is the year when the sales growth inflection rate becomes apparent. I personally have been waiting for this inflection point for two years. So it would be very welcome. It is hard to understand how cheaper, faster, less hands on effort, less test failures etc, does not translate into a successful product. Welcome to the board. FL
Einde dag ingestapt, heb zo het vermoeden dat dit bedrijf eerdaahs met onverwacht goed nieuws komt.
€ URO-Trader Welcome aboard. However, I'm not sure it will be a great short term trade. We can expect to hear that Gene Fusion is being released in the next few weeks. I hope ImmunExpress presents the results of the their Covid Triage study and hopefully a 510K approval in the next month or so. The cartridge volume and sales growth inflection is likely a 2nd half story. The majority of the Idylla products are still oncology based and the resumption of procedures colonoscopies, cytology etc. will not likely reach normal limits until most residents of a country have been vaccinated or until the patient feels the risk of virus infection is less than the risk of delaying the exam. I've come to grips with the fact that MDx is very early in the adoption curve. Idylla seeks to disrupt the standard methods of MDx (Sanger sequencing, pyrosequencing, immunohistochemistry, NGS, etc.) by providing accurate results on-demand, faster, cheaper, without interpretation of genetic counselors, etc. But I don't believe that this type of disruption can occur before the procedures is widely approved for diagnostic use and not just RUO. The good news is that the numerous journal articles I've read indicate that Idylla is accurate and sensitive and should be approved. The bad news is we are two years and counting waiting for BCART to make their registration case in the US, China and Japan. Some of this delay is clearly the fault of the regulating agencies (i.e., FDA) in that they have failed to modernize the IVD approval process. But I think BCART and their partners may also have some responsibility for the delays. I've often pointed to Cepheid as a good analogy for BCART. Their cartridge based MDx testing for infectious disease has grown at roughly 20% for the past 15 years. Assuming oncology MDx makes the same move to the POC market, I believe BCART is capable of similar growth. FL
Hello Flatlander, Thanks a lot for your interesting feedback. Based on the first analysis I did, I have bought my first batch of Biocartis shares. Still have to do further analysis to see what weight in my portfolio can be given to this company. Must say that the cooperations, multiple different activities/possibilities look interesting. Kind regards, Thole
Thole My vantage point is a bit skewed. All assets in the U.S have run hard and valuations and potential future returns are not very enticing. I've waded into the EU and EM looking for better valuations and growth prospects. Biocartis is at a crossroads, They have launched a very differentiated MDx product into world markets that are growing at 20% a year but it remains to be seen whether they have the technical horses to secure the registrations to fully unlock these markets. I've done a ton of homework reviewing pathology journals to determine that Idylla is differentiated enough to gain traction against huge competitors. I'm encouraged that several articles have flow charted how idylla can be used synergistically with NGS in the existing lab workflow. I believe that the future prospects have only improved as a result of COVID. Being able to provide complex MDx results in a contactless manner without much hands on technician effort is an advantage in this type of environment. BCART can help their case by demonstrating that the new flex cartridge will accelerate the introduction of new assay content. I also, think BCART will double in the next 18 months if they deliver on their promise to file and succeed in achieving IVD registrations in the US, Japan and China. Long story short. I can see a 2 down 10 up potential risk/reward ratio in the next 5 years. Companies in the US have $2-5B valuations without having the potential disruptive advantages that BCART has, But management needs to start demonstrating that they can deliver.on the promise. FL
Biotech en farma blijft een boeiende sector, iedereen kan wel een idee hebben wat er zal gebeuren maar niemand weet het zeker. Kijk maar naar Galapagos, op twee jaar tijd drie grote tegenslagen en de beurswaarde is gesmolten als sneeuw voor de zon. Laat ons hopen dat er bij Biocartis eindelijk eens een positieve omslag plaatsvindt. Binnen een paar weken weten we al veel meer.
In de regel, bij geen nieuws koers gematigd lager. Zodra er nieuws komt moet je ze in bezit hebben, anders is men te laat. Tijdspanne is veelal een investering in kennis, welke zich uiteindelijk vertaald is een koersstijging. De laatste cijfers vond ik positief en een onverwachte wending kan een behoorlijke boost geven. Vandaar de investering. Mocht de koers omlaag gaan middel ik is mijn besluit.
As a rule, BCART has shown not to support any sustained share price increase as a result of any of the following: Technical journal article presenting positive findings; Launch of a new assay RUO; Announcement of a new product development partnership. The market seems to be in "show me mode", I suspect that announcement of an IVD registration in any geography would be huge positives, as would a CDx launch with one of the major pharma partners. Otherwise, the market is looking for increases in console placements and cartridge sales. Long story short, the news needs to show a pathway to expedited profitability to result in significant lasting gains. FL
FL, thx for your extensive feedback (as always). BCART needs to start growing up and management needs to get his act together this year, or I (and I think I'm not the only one) will start to lose my patience.. Implementing the things you mentioned above would be a good start to reassure that confidence.
In my opinion Biocartis is a company that evolves to slow and that doesn't dare to think and dream big. Their products and services seem to be good if you look at the latest financial reports that are available, but they need to dream bigger. In the world that they live in you've got to be innovative, smart and fast. I hope the financial results that will come out on February 25 will boost the stock price, because looking at the potential (which I strongly believe in) I can't understand why they didn't recover from COVID-19 downgrade.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee